SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+13.1%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$273M
AUM Growth
+$273M
(+27%)
Cap. Flow
+$37.2M
Cap. Flow
% of AUM
13.63%
Top 10 Holdings %
Top 10 Hldgs %
31.23%
Holding
76
New
17
Increased
24
Reduced
16
Closed
9
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$9.26M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$7.3M |
| 3 |
Gilead Sciences
GILD
|
$6.37M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$4.91M |
| 5 |
AbbVie
ABBV
|
$4.35M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$6.73M |
| 2 |
Zimmer Biomet
ZBH
|
$4.88M |
| 3 |
Bristol-Myers Squibb
BMY
|
$4.21M |
| 4 |
Tenet Healthcare
THC
|
$3.99M |
| 5 |
AstraZeneca
AZN
|
$3.89M |
Sector Composition
| 1 | Healthcare | 87.53% |
| 2 | Financials | 2.5% |
| 3 | Energy | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.4M | 4.9% | 110,000 +60,000 | +120% | +$7.3M |
|
2
UnitedHealth
UNH
$281B
| $9.74M | 3.56% | 52,500 +7,500 | +17% | +$1.39M |
|
|
3
Johnson & Johnson
JNJ
$427B
| $9.26M | 3.39% | +70,000 | New | +$9.26M |
|
4
Humana
HUM
$36.5B
| $8.42M | 3.08% | 35,000 | – | – |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $7.79M | 2.85% | 60,000 +12,500 | +26% | +$1.62M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.72M | 2.83% | 85,000 +30,000 | +55% | +$2.72M |
|
7
Incyte
INCY
$16.5B
| $7.56M | 2.77% | 60,000 +10,000 | +20% | +$1.26M |
|
8
Elevance Health
ELV
$71.8B
| $7.53M | 2.75% | 40,000 -3,795 | -9% | -$714K |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $7.09M | 2.59% | 55,000 +5,000 | +10% | +$644K |
|
|
AET
10
DELISTED
Aetna Inc
AET
| $6.83M | 2.5% | 45,000 -9,900 | -18% | -$1.5M |
|
11
Cigna
CI
$80.3B
| $6.7M | 2.45% | 40,000 -8,504 | -18% | -$1.42M |
|
12
Boston Scientific
BSX
$156B
| $6.65M | 2.44% | 240,000 +40,000 | +20% | +$1.11M |
|
13
Centene
CNC
$14.3B
| $6.39M | 2.34% | 80,000 +15,000 | +23% | +$1.2M |
|
|
14
Gilead Sciences
GILD
$140B
| $6.37M | 2.33% | +90,000 | New | +$6.37M |
|
|
WCG
15
DELISTED
Wellcare Health Plans, Inc.
WCG
| $6.29M | 2.3% | 35,000 -20,000 | -36% | -$3.59M |
|
16
Baxter International
BAX
$12.7B
| $6.05M | 2.22% | 100,000 -10,000 | -9% | -$605K |
|
17
Molina Healthcare
MOH
$9.8B
| $5.71M | 2.09% | 82,500 +62,500 | +313% | +$4.32M |
|
18
Revvity
RVTY
$10.5B
| $5.45M | 2% | 80,000 -10,000 | -11% | -$681K |
|
19
Biogen
BIIB
$19.4B
| $5.43M | 1.99% | 20,000 +5,000 | +33% | +$1.36M |
|
20
Cencora
COR
$56.5B
| $5.2M | 1.9% | 55,000 +10,000 | +22% | +$945K |
|
21
McKesson
MCK
$85.4B
| $4.94M | 1.81% | 30,000 | – | – |
|
|
22
Regeneron Pharmaceuticals
REGN
$61.5B
| $4.91M | 1.8% | +10,000 | New | +$4.91M |
|
23
Becton Dickinson
BDX
$55.3B
| $4.88M | 1.79% | 25,000 +5,000 | +25% | +$976K |
|
24
Abbott
ABT
$231B
| $4.86M | 1.78% | 100,000 | – | – |
|
25
Merck
MRK
$210B
| $4.81M | 1.76% | 75,000 | – | – |
|